HOME > BUSINESS
BUSINESS
- Teijin to Receive US$5 Million Milestone as Narcolepsy Drug Enters European PI
November 28, 2025
- Izervay, Vorzzz, Dormicum Syrup Now Available in Japan
November 28, 2025
- Meiji Seeks Label Expansion for Laserphyrin in Cervical Intraepithelial Neoplasia
November 28, 2025
- Jardiance Tops 7 Categories in October Promotion Rankings: Intage
November 28, 2025
- Otsuka’s Sibeprenlimab Earns FDA’s Accelerated Nod for IgAN
November 27, 2025
- Japan PIII Trial Begins for Kagoshima University Spinout’s Oncolytic Virus
November 27, 2025
- Mochida, Ayumi Curb Shipments of Humira Biosimilar 40 mg amid Surging Orders
November 27, 2025
- Toray Out-Licenses Peripheral Neuropathy Drug to Sanodyne
November 27, 2025
- Renalys’ IgAN Drug Nets Positive PIII Data, 2026 Japan Filing on Track
November 27, 2025
- Rolling Submission for Leqembi SC Starting Dose Completed in US
November 27, 2025
- Taisho Touts Low Next-Day Carryover for New Insomnia Drug Vorzzz
November 26, 2025
- Alfresa/Mycenax-Led Biosimilar JV to Be Named Alfenax Biologics
November 26, 2025
- Chugai Targets Japan Filing in 2026 for Ranibizumab Eye Implant
November 26, 2025
- Allergan Japan Files TrenibotE for Glabellar Lines Treatment
November 26, 2025
- Taiho Begins Rolling US NDA Submission for Zipalertinib
November 26, 2025
- Padcev/Keytruda Wins US Nod for Perioperative Bladder Cancer Use
November 26, 2025
- Otsuka Files Novel ADHD Drug Centanafadine in US
November 26, 2025
- Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts
November 26, 2025
- Eisai to Unify Global HR Framework by 2029 to Bolster Leqembi Growth
November 25, 2025
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
